Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | EVP, Chief Medical Officer | June 17, 2026 | June 22, 2026 |
| Viracta Therapeutics, Inc.VIRX · Entity 85616 | Chief Medical Officer | March 16, 2023 | March 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RIGEL PHARMACEUTICALS INC
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.90 · Expires 2034-03-27 | Direct | 9,375 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 9,375 · Balance 9,375 F1: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F2: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.49 · Expires 2035-01-29 | Direct | 7,394 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 7,394 · Balance 7,394 F3: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F4: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
F2: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.
F3: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
F4: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.
Viracta Therapeutics, Inc.
Report date March 16, 2023 · Filed March 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2033-03-16 | Direct | 150,000 |
Reported balance
After 2023-03-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-16 · Grant · Acquired 150,000 · Balance 150,000 F1: 1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:11 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 7,394 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-26-003040 · form4.xml · derivative · entry 2 Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,394 Underlying: Common Stock · 7,394 shares Expires 2035-01-29 F3 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F3 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F4 · derivative.exercise_date: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. F3 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:11 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 9,375 | $0.00 Strike: $14.90 | $0.00 |
DisclosureSEC source: 0000905148-26-003040 · form4.xml · derivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 9,375 shares Expires 2034-03-27 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 850 | $29.86 | $25,381.00 |
DisclosureSEC source: 0000905148-26-002809 · form4.xml · nonDerivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,003 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 18,894 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000953 · form4.xml · nonDerivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,853 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 3,758 | $34.62 | $130,101.96 |
DisclosureSEC source: 0000905148-26-000677 · form4.xml · nonDerivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,959 Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 7,394 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-25-003349 · form4.xml · derivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,394 Underlying: Common Stock · 7,394 shares Expires 2035-01-29 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 00:56 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 9,375 | $0.00 Strike: $14.90 | $0.00 |
DisclosureSEC source: 0000905148-25-000978 · form4.xml · derivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 9,375 shares Expires 2034-03-27 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 23:47 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,788 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-25-000302 · form4.xml · derivative · entry 2 Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,788 Underlying: Common Stock · 14,788 shares Expires 2035-01-29 F2 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continuous service to the Issuer through each such period. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 23:47 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 19,717 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000302 · form4.xml · nonDerivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,717 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 10, 2025, with the first annual vest occurring on February 10, 2026. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:09 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 187,500 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0000905148-24-001016 · form4.xml · derivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2034-03-27 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to this option vest on March 11, 2025, and 1/48th of the shares subject to this option vest in substantially equal monthly installments over the thirty-six (36) months thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 17:03 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-23-019742 · doc4.xml · derivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-03-16 F1 · derivative.exercise_date: 1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2023. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 18:28 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | SaleCommon Stock | 2,156 | $1.68 | $3,624.67 |
DisclosureSEC source: 0001209191-23-013866 · doc4.xml · nonDerivative · entry 2 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,087 F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction. F3 · price: Represents the weighted average share price of an aggregate total of 2,116 shares sold in the price range of $1.68 to $1.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 18:28 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionRestricted Stock Units · Derivative | 4,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013866 · doc4.xml · derivative · entry 3 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,146 Underlying: Common Stock · 4,127 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 18:28 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionCommon Stock | 4,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013866 · doc4.xml · nonDerivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 17:25 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | SaleCommon Stock | 2,116 | $2.72 | $5,754.04 |
DisclosureSEC source: 0001209191-22-058974 · doc4.xml · nonDerivative · entry 2 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,116 F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction. F3 · price: Represents the weighted average share price of an aggregate total of 2,116 shares sold in the price range of $2.68 to $2.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 17:25 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionRestricted Stock Units · Derivative | 4,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058974 · doc4.xml · derivative · entry 3 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,273 Underlying: Common Stock · 4,127 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 17:25 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionCommon Stock | 4,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058974 · doc4.xml · nonDerivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 21:18 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | SaleCommon Stock | 2,190 | $4.01 | $8,785.84 |
DisclosureSEC source: 0001209191-22-047951 · doc4.xml · nonDerivative · entry 2 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,105 F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction. F3 · price: Represents the weighted average share price of an aggregate total of 2,190 shares sold in the price range of $4.01 to $4.04 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 25, 2022 Filed Aug 29, 2022 21:18 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionRestricted Stock Units · Derivative | 4,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047951 · doc4.xml · derivative · entry 3 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,400 Underlying: Common Stock · 4,127 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. Read SEC document |
| August 25, 2022 Filed Aug 29, 2022 21:18 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionCommon Stock | 4,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047951 · doc4.xml · nonDerivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. Read SEC document |
| May 26, 2022 Filed May 27, 2022 17:32 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | SaleCommon Stock | 2,154 | $1.90 | $4,094.97 |
DisclosureSEC source: 0001209191-22-032670 · doc4.xml · nonDerivative · entry 2 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,168 F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction. F3 · price: Represents the weighted average share price of an aggregate total of 2,154 shares sold in the price range of $1.90 to $1.95 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 25, 2022 Filed May 27, 2022 17:32 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionRestricted Stock Units · Derivative | 4,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032670 · doc4.xml · derivative · entry 3 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,527 Underlying: Common Stock · 4,127 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. Read SEC document |
| May 25, 2022 Filed May 27, 2022 17:32 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionCommon Stock | 4,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032670 · doc4.xml · nonDerivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 17:34 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001209191-22-020078 · doc4.xml · derivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-03-17 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option shall vest on the date one month following February 23, 2022 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:12 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | SaleCommon Stock | 2,395 | $2.78 | $6,656.90 |
DisclosureSEC source: 0001209191-22-014441 · doc4.xml · nonDerivative · entry 2 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,195 F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction. F3 · price: Represents the weighted average share price of an aggregate total of 2,395 shares sold in the price range of $2.7101 to $2.84 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:12 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionRestricted Stock Units · Derivative | 4,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014441 · doc4.xml · derivative · entry 3 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,654 Underlying: Common Stock · 4,127 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:12 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionCommon Stock | 4,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014441 · doc4.xml · nonDerivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. Read SEC document |
| November 29, 2021 Filed Nov 29, 2021 19:50 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | SaleCommon Stock | 2,591 | $4.82 | $12,486.29 |
DisclosureSEC source: 0001209191-21-067046 · doc4.xml · nonDerivative · entry 3 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,463 F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction. F4 · price: Represents the weighted average share price of an aggregate total of 2,591 shares sold in the price range of $4.62 to $5.34 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 26, 2021 Filed Nov 29, 2021 19:50 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | SaleCommon Stock | 1,950 | $4.80 | $9,361.17 |
DisclosureSEC source: 0001209191-21-067046 · doc4.xml · nonDerivative · entry 2 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,054 F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction. F3 · price: Represents the weighted average share price of an aggregate total of 1,950 shares sold in the price range of $4.7150 to $5.01 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2021 Filed Nov 29, 2021 19:50 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionRestricted Stock Units · Derivative | 8,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-067046 · doc4.xml · derivative · entry 4 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,781 Underlying: Common Stock · 8,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. F5 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. F5 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year. Read SEC document |
| November 25, 2021 Filed Nov 29, 2021 19:50 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionCommon Stock | 8,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-067046 · doc4.xml · nonDerivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. Read SEC document |
| May 11, 2021 Filed May 13, 2021 17:46 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,061 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001209191-21-032413 · doc4.xml · derivative · entry 4 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,956 Underlying: Common Stock · 2,061 shares Expires 2031-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One forty-eighth (1/48th ) of the Shares subject to the Option shall vest on February 28, 2021, and one forty-eighth (1/48th ) of the total Shares subject to the Option shall vest each month thereafter on the last day of such month, subject to the reporting person continuing to be a Service Provider (as defined in the Plan) through each such date. Read SEC document |
| May 11, 2021 Filed May 13, 2021 17:46 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionStock Option (Right to Buy) · Derivative | 32,689 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001209191-21-032413 · doc4.xml · derivative · entry 3 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,069 Underlying: Common Stock · 32,689 shares Expires 2030-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of May 1, 2020 (the "Vesting Commencement Date"), and one forty-eighth (1/48th ) of the total shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through each such date. Read SEC document |
| May 11, 2021 Filed May 13, 2021 17:46 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionCommon Stock | 2,061 | $3.58 | $7,378.38 |
DisclosureSEC source: 0001209191-21-032413 · doc4.xml · nonDerivative · entry 2 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 13, 2021 17:46 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | Exercise / conversionCommon Stock | 32,689 | $1.26 | $41,188.14 |
DisclosureSEC source: 0001209191-21-032413 · doc4.xml · nonDerivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 20:28 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 126,890 | $0.00 Strike: $8.74 | $0.00 |
DisclosureSEC source: 0001209191-21-023669 · doc4.xml · derivative · entry 1 Rojkjaer Lisa · CIK 0001846460 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,890 Underlying: Common Stock · 126,890 shares Expires 2031-03-26 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 26, 2021 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.